A Pilot Study Suggests that the G/G Genotype of Resistin Single Nucleotide Polymorphism at -420 May Be an Independent Predictor of a Reduction in Fasting Plasma Glucose and Insulin Resistance by Pioglitazone in Type 2 Diabetes

Hideichi MAKINO; Ikki SHIMIZU; Satoshi MURAO; Shiori KONDO; Yasuharu TABARA; Masao FUJIYAMA; Yasuhisa FUJII; Yasuharu TAKADA; Kazuaki NAKAI; Kenichi IZUMI; Jun OHASHI; Ryoichi KAWAMURA; Junko YAMAUCHI; Yasunori TAKATA; Wataru NISHIDA; Mitsuru HASHIRAMOTO; Hiroshi ONUMA; Haruhiko OSAWA

doi:10.1507/endocrj.K08E-320

ORIGINALS

A Pilot Study Suggests that the G/G Genotype of Resistin Single Nucleotide Polymorphism at -420 May Be an Independent Predictor of a Reduction in Fasting Plasma Glucose and Insulin Resistance by Pioglitazone in Type 2 Diabetes

Hideichi MAKINO, Ikki SHIMIZU, Satoshi MURAO, Shiori KONDO, Yasuharu TABARA, Masao FUJIYAMA, Yasuhisa FUJII, Yasuharu TAKADA, Kazuaki NAKAI, Kenichi IZUMI, Jun OHASHI, Ryoichi KAWAMURA, Junko YAMAUCHI, Yasunori TAKATA, Wataru NISHIDA, Mitsuru HASHIRAMOTO, Hiroshi ONUMA, Haruhiko OSAWA

Author information

Hideichi MAKINO
Institute of Diabetes Research Center, Takanoko Hospital, Ehime, Japan
Department of Molecular and Genetic Medicine, Ehime University, Graduate School of Medicine, Ehime, Japan
Ikki SHIMIZU
Ehime Prefectural Central Hospital, Ehime, Japan
Satoshi MURAO
Matsuyama-Shimin Hospital, Ehime, Japan
Shiori KONDO
Matsuyama Red Cross Hospital, Ehime, Japan
Yasuharu TABARA
Department of Basic Medical Research and Education,Ehime University Graduate School of Medicine, Ehime, Japan
Masao FUJIYAMA
Fujiyama Clinic, Ehime, Japan
Yasuhisa FUJII
Institute of Diabetes Research Center, Takanoko Hospital, Ehime, Japan
Yasuharu TAKADA
Saijo Central Hospital, Ehime, Japan
Kazuaki NAKAI
Ehime Rosai Hospital, Ehime, Japan
Kenichi IZUMI
Matsuyama Red Cross Hospital, Ehime, Japan
Jun OHASHI
Doctoral Program in Life System Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
Ryoichi KAWAMURA
Department of Molecular and Genetic Medicine, Ehime University, Graduate School of Medicine, Ehime, Japan
Junko YAMAUCHI
Department of Molecular and Genetic Medicine, Ehime University, Graduate School of Medicine, Ehime, Japan
Yasunori TAKATA
Department of Molecular and Genetic Medicine, Ehime University, Graduate School of Medicine, Ehime, Japan
Wataru NISHIDA
Department of Molecular and Genetic Medicine, Ehime University, Graduate School of Medicine, Ehime, Japan
Mitsuru HASHIRAMOTO
Department of Molecular and Genetic Medicine, Ehime University, Graduate School of Medicine, Ehime, Japan
Hiroshi ONUMA
Department of Molecular and Genetic Medicine, Ehime University, Graduate School of Medicine, Ehime, Japan
Ehime Proteo-Medicine Research Center, Ehime, Japan
Haruhiko OSAWA
Department of Molecular and Genetic Medicine, Ehime University, Graduate School of Medicine, Ehime, Japan
Ehime Proteo-Medicine Research Center, Ehime, Japan

Keywords: Pioglitazone, Resistin, SNP, Insulin resistance, Type 2 diabetes

JOURNAL FREE ACCESS

2009 Volume 56 Issue 9 Pages 1049-1058

DOI https://doi.org/10.1507/endocrj.K08E-320

View "Advance Publication" version (September 9, 2009).

Details

Abstract

The aim of this study was to determine the relation between the G/G genotype of a resistin gene promoter single nucleotide polymorphism (SNP) at -420 (rs1862513) and glycemic control by pioglitazone in type 2 diabetes. In Study 1, 121 type 2 diabetic patients were treated with pioglitazone (15 or 30 mg/day) for 12 weeks, in addition to previous medication. In Study 2, 63 patients who had been treated with pioglitazone for 12 weeks were examined retrospectively. In Study 1, multiple regression analysis revealed that the G/G but not C/G genotype was correlated with a reduction in fasting plasma glucose (FPG) and homeostasis model assessment of insulin resistance (HOMA-IR) compared to C/C. When adjusted for age, gender, and BMI, the G/G genotype was an independent factor for the reduction of FPG (P=0.020) and HOMA-IR (P =0.012). When studies 1 and 2 were combined by adjusting the studies, age, gender, and BMI, the reduction of HbA1c was correlated with the G/G genotype (β=-0.511, P=0.044). Therefore, this pilot study suggests that the G/G genotype of resistin SNP –420 may be an independent predictor of the reduction of fasting plasma glucose and HOMA-IR by pioglitazone.

Corresponding author

Register with J-STAGE for free!